Jonathan Sporn

Gilgamesh Pharmaceuticals, a biotechnology company that uses psychedelic-related drugs to treat neuropsychiatric disorders, reported Thursday it has raised $27 million in a Series A funding round led by Prime Movers Lab. Other investors involved in the round included the Noetic Psychedelic Fund LP...